Based on the principle of competitive binding
Store as packaged in the sealed pouch at temperature (4-30℃ or 40-86℉)
Lateral flow chromatographic immunoassay
Qualitative detection rapid test kit AMRDT110
Qualitative detection rapid test kit AMRDT110 is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:
| Test | Calibrator | Cut-off (ng/mL) |
| Amphetamine (AMP1000) | D-Amphetamine | 1,000 |
| Amphetamine (AMP500) | D-Amphetamine | 500 |
| Amphetamine (AMP300) | D-Amphetamine | 300 |
| Benzodiazepines (BZO300) | Oxazepam | 300 |
| Benzodiazepines (BZO200) | Oxazepam | 200 |
| Barbiturates (BAR) | Secobarbital | 300 |
| Buprenorphine (BUP) | Buprenorphine | 10 |
| Cocaine (COC) | Benzoylecgonine | 300 |
| Cotinine (COT) | Cotinine | 200 |
| Methadone metabolite (EDDP) | 2-Ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine | 100 |
| Fentanyl (FYL) | Fentanyl | 200 |
| Ketamine (KET) | Ketamine | 1,000 |
| Synthetic Cannabinoid (K2 50) | JWH-018 5-pentanoic acid/ JWH-073 4-Butanoic acid | 50 |
| Synthetic Cannabinoid (K2 200) | JWH-018 5-pentanoic acid/ JWH-073 4-Butanoic acid | 200 |
| Methamphetamine (mAMP1000/ MET1000) | D-Methamphetamine | 1,000 |
| Methamphetamine (mAMP500/ MET500) | D-Methamphetamine | 500 |
| Methamphetamine (mAMP300/ MET300) | D-Methamphetamine | 300 |
| Methylenedioxymethamphetamine (MDMA) | D,L-Methylenedioxymethamphetamine | 500 |
| Morphine (MOP300/ OPI300) | Morphine | 300 |
| Methadone (MTD) | Methadone | 300 |
| Methaqualone (MQL) | Methaqualone | 300 |
| Opiates (OPI 2000) | Morphine | 2,000 |
| Oxycodone (OXY) | Oxycodone | 100 |
| Phencyclidine (PCP) | Phencyclidine | 25 |
| Propoxyphene (PPX) | Propoxyphene | 300 |
| Tricyclic Antidepressants (TCA) | Nortriptyline | 1,000 |
| Marijuana (THC) | 11-nor-Δ9-THC-9-COOH | 50 |
| Tramadol (TRA) | Tramadol | 200 |
Configurations of the Qualitative detection rapid test kit AMRDT110 can consist of any combination of the above listed drug analytes.
The Qualitative detection rapid test AMRDT110 is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody.
During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.
A drug-positive urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.
To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.
